Calliditas Therapeutics announces license agreement with Viatris to register and commercialize specialty therapy for IgA nephropathy in Japan
Calliditas announces that it has entered into an agreement with Viatris to bring Nefecon[®], a specialty therapy focused on downregulating IgA1, to Japanese patients. The agreement, worth up to $100M in upfront and milestone payments, combines Calliditas’ specifically formulated drug candidate with Viatris’ development, marketing and sales expertise. Stockholm, Sweden; December 13, 2022 – Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) announced today that they have entered into an exclusive license agreement with Viatris Pharmaceuticals Japan Inc., a